placebo + capecitabine + oxaliplatin

This combination therapy serves as the control arm in Phase III clinical trials conducted by Suzhou Suncadia Biopharmaceuticals for the treatment of gastric and gastroesophageal junction (GEJ) cancers. It consists of a placebo (matching an experimental agent such as the PD-L1/TGF-βRII bifunctional fusion protein SHR-1701) administered in conjunction with the CAPOX chemotherapy regimen. CAPOX is a standard-of-care doublet chemotherapy comprising capecitabine, an oral fluoropyrimidine carbamate prodrug that is converted to 5-fluorouracil to inhibit thymidylate synthase, and oxaliplatin, a platinum-based antineoplastic agent that induces DNA cross-linking. This regimen is primarily utilized as a first-line treatment for advanced or metastatic HER2-negative gastric adenocarcinoma.

Other names

placebo + CAPOXplacebo + XELOXPlacebo plus CAPOXPlacebo plus chemotherapy